Sprint Bioscience Valuation
| SPRINT Stock | SEK 1.82 0.02 1.09% |
Based on Macroaxis valuation methodology, the company appears to be overvalued. Sprint Bioscience has a current Real Value of kr1.45 per share. The regular price of the company is kr1.82. Our model measures the value of Sprint Bioscience from inspecting the company fundamentals such as Shares Owned By Insiders of 35.31 %, return on equity of -1.09, and Current Valuation of 24.98 M as well as reviewing its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Sprint Bioscience's price fluctuation is dangerous at this time. Calculation of the real value of Sprint Bioscience is based on 3 months time horizon. Increasing Sprint Bioscience's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Sprint Bioscience is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Sprint Stock. However, Sprint Bioscience's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 1.82 | Real 1.45 | Hype 1.82 | Naive 2.15 |
The real value of Sprint Stock, also known as its intrinsic value, is the underlying worth of Sprint Bioscience Company, which is reflected in its stock price. It is based on Sprint Bioscience's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Sprint Bioscience's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Sprint Bioscience AB helps investors to forecast how Sprint stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Sprint Bioscience more accurately as focusing exclusively on Sprint Bioscience's fundamentals will not take into account other important factors: Sprint Bioscience Total Value Analysis
Sprint Bioscience AB is at this time projected to have takeover price of 24.98 M with market capitalization of 53.17 M, debt of 0, and cash on hands of 13.82 M. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Sprint Bioscience fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
24.98 M | 53.17 M | 0 | 13.82 M |
Sprint Bioscience Investor Information
About 35.0% of the company outstanding shares are owned by corporate insiders. The book value of Sprint Bioscience was at this time reported as 0.63. The company recorded a loss per share of 0.75. Sprint Bioscience had not issued any dividends in recent years. The entity had 356:303 split on the 27th of October 2022. Based on the measurements of operating efficiency obtained from Sprint Bioscience's historical financial statements, Sprint Bioscience AB is not in a good financial situation at the moment. It has a very high risk of going through financial straits in December.Sprint Bioscience Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Sprint Bioscience has an asset utilization ratio of 44.37 percent. This suggests that the Company is making kr0.44 for each dollar of assets. An increasing asset utilization means that Sprint Bioscience AB is more efficient with each dollar of assets it utilizes for everyday operations.Sprint Bioscience Ownership Allocation
Sprint Bioscience shows a total of 69.8 Million outstanding shares. Sprint Bioscience maintains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Please note that no matter how many assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it.Sprint Bioscience Profitability Analysis
The company reported the revenue of 35.11 M. Net Loss for the year was (25.08 M) with profit before overhead, payroll, taxes, and interest of 24.59 M.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Sprint Bioscience's worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Sprint Bioscience and how it compares across the competition.
About Sprint Bioscience Valuation
The stock valuation mechanism determines Sprint Bioscience's current worth on a weekly basis. Our valuation model uses a comparative analysis of Sprint Bioscience. We calculate exposure to Sprint Bioscience's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Sprint Bioscience's related companies.Sprint Bioscience AB develops pharmaceutical products in the areas of cancer and metabolism. Sprint Bioscience AB was founded in 2009 and is based in Huddinge, Sweden. Sprint Bioscience operates under Pharmaceuticals And Biosciences classification in Sweden and is traded on Stockholm Stock Exchange.
8 Steps to conduct Sprint Bioscience's Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Sprint Bioscience's potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Sprint Bioscience's valuation analysis, follow these 8 steps:- Gather financial information: Obtain Sprint Bioscience's financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Sprint Bioscience's revenue streams: Identify Sprint Bioscience's primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Sprint Bioscience's industry and market trends, including the size of the market, growth rate, and competition.
- Establish Sprint Bioscience's growth potential: Evaluate Sprint Bioscience's management, business model, and growth potential.
- Determine Sprint Bioscience's financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Sprint Bioscience's estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Complementary Tools for Sprint Stock analysis
When running Sprint Bioscience's price analysis, check to measure Sprint Bioscience's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sprint Bioscience is operating at the current time. Most of Sprint Bioscience's value examination focuses on studying past and present price action to predict the probability of Sprint Bioscience's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sprint Bioscience's price. Additionally, you may evaluate how the addition of Sprint Bioscience to your portfolios can decrease your overall portfolio volatility.
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device |